AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00763360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Healon
Description: Injection of Healon into the anterior chamber prior to and throughout the cataract surgery procedure
Study NCT00763360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amvisc Plus
Description: Injection of Amvisc Plus into the anterior chamber prior to and throughout the cataract surgery procedure
Study NCT04724746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure and Cognitive Behavioral Therapy
Description: Intervention involves writing details about a recent sexual assault and coping skills for substance use.
Study NCT02832778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Efavirenz 400mg
Study NCT02832778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir /emtricitabine
Description: tenofovir 245 mg/emtricitabine 200mg
Study NCT02832778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir/lamivudine
Description: tenofovir 245mg/lamivudine 300mg
Study NCT02832778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamivudine/zidovudine
Description: lamivudine 300mg/zidovudine 600mg
Study NCT02832778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifinah or local generics
Description: Rifampicin 600 mg and isoniazid 300 mg if ≥50kg or rifampicin 450 mg and isoniazid 300 mg if \<50kg.)
Study NCT04102137 — intervention group
Intervention type: BIOLOGICAL
Intervention: Pertagen (aP BioNet)
Description: Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region.
Study NCT04102137 — intervention group
Intervention type: BIOLOGICAL
Intervention: Boostagen (TDaP BioNet)
Description: Boostagen (TDaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TDaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TDaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region.
Study NCT04102137 — intervention group
Intervention type: BIOLOGICAL
Intervention: Adacel
Description: Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region.
Study NCT03434483 — intervention group
Intervention type: PROCEDURE
Intervention: Assessment of the atherosclerotic plaque in a moderate lession.
Description: In patients who have been successfully revascularized the artery responsible for AMI and also present an intermediate lesion (40-80%) in another coronary territory, the clinical care protocol of the Cardiology Service stipulates the need for a physiological assessment with guidance of pressure (FFR).~The thickness of the fibrous cap shall be measured using optical coherence tomography.~In addition to the FFR measurement, a complete physiological assessment with a Doppler-pressure guide. This will allow the procedure to be performed without additional risk to the patient. The physiological study will include the analysis of endothelium-dependent vascular function and endothelium-independent vascular function.
Study NCT03434483 — intervention group
Intervention type: GENETIC
Intervention: Gene variants in atherosclerosis
Description: From the blood samples of the patients, the total DNA will be extracted and the main functional variants identified in the literature will be genotyped
Study NCT03434483 — intervention group
Intervention type: OTHER
Intervention: Microbiota analysis
Description: From the samples of blood, feces, oral cavity and blood, the DNA of the microbiota will be extracted using specific extraction kits and the microbiome will be analyzed through the study of 16S ribosomal RNA amplicons.
Study NCT03434483 — intervention group
Intervention type: OTHER
Intervention: Immunological analysis
Description: A study of immunological cell populations and cytokines will be carried out from fresh blood samples using antibody panels and flow cytometry
Study NCT03434483 — intervention group
Intervention type: OTHER
Intervention: Clinical evaluation
Description: Clinical evaluation including hemostasis and biochemical studies and questionaries for diet and exercice registration
Study NCT04042584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visio conference device evaluation (DVCM)
Description: Standard neurological tele-evaluation (limited to 15minutes) remotely carried out by a first neurologist via a tablet (DVCM) and an operator. A second neurologist assist at the assessment without intervention next to the patient. Once the remote assessment is complet, the second neurologist ensure the continuation of standard patient care.
Study NCT00598728 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionaires
Description: A patient questionnaire, which includes questions on medical morbidities and QOL, will be mailed to participants.
Study NCT03323593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: blood is sampled for quantification of plasma concentration after intravenous, intranasal by atomisation and intranasal by drops.
Study NCT04472221 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterioarterial synthetic graft
Description: Synthetic poly tetraflouroethylene graft
Study NCT02823470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM/IVA
Description: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
Study NCT02823470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: activated smart device
Study NCT02823470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: de-activated smart device
Study NCT04356157 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioural change interventions
Description: The study evaluates three different interventions aimed at improving adherence and retention to Anti Retroviral therapy among HIV positive women through engagement with their life partner. The interventions are 1) opening the facility once a month, only for men, special day; 2) testing peer-to-peer counselling among men, male champions; 3) providing incentive to all women accompanied by their partners at the facility, nudge or incentive.
Study NCT03594929 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active RIC
Study NCT03594929 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Study NCT02365662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-221
Description: ABBV-221 will be given either every 3 weeks or 2 weeks on, 1 week off or weekly dosing by intravenous infusion approximately over 30 minutes to 3 hours. This is a dose escalation study, therefore the dose of ABBV-221 will change throughout the study.
Study NCT05108766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Description: Tildrakizumab 100 mg administered SC. Each PFS contains 1 mL of solution, tildrakizumab 100 mg/mL.
Study NCT05108766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to tildrakizumab administered SC
Study NCT02548286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan 8mg
Description: PO, 1day or 22day
Study NCT02548286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5mg
Description: PO, 1day or 22day
Study NCT02548286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 8/5mg
Description: PO, 1day or 22day
Study NCT04255199 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Clinicians randomized to the control group will receive a single visit with a standardized patient instructor (SPI) scheduled during usual office hours. SPIs will portray a patients with acute back pain but will deliver no formative training or feedback to the primary care physicians randomized to the control arm.
Study NCT04255199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Clinicians randomized to the intervention group will receive 2-3 visits with a standardized patient instructor (SPI) scheduled during usual office hours over \~3 month period. For intervention physicians, SPIs will portray patients with acute back pain and will provide formative feedback to physicians and specific instruction in communication techniques to facilitate patient acceptance of a watchful waiting strategy with respect to spinal imaging. The specific communication techniques and sequence will be determined based on pre-trial literature review, patient focus groups, and interviews of primary care physicians who will not participate in the trial.
Study NCT00993005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cicatrix
Description: Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the scar rubbing in different directions for 2 minutes, three times a day, for 12 weeks.
Study NCT00993005 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the scar rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
Study NCT06155188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: applying of FLU+CY post-HSCT
Description: The conditioning regimen (PT-Cy/Flu group) consisted of fludarabine (40mg/m2, d-5 to d-3 and d+3, d+4), busulfan (100mg/m2, d-6 to d-3), haplo-PBSC (d0), PTCy (50mg/kg, d+3, d+4) and UCB (d+6).
Study NCT01123070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TL011, anti CD20, for the treatment of rheumatoid arthritis
Description: TL011 administered by 2 infusions, 2 weeks apart
Study NCT01123070 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MabThera infusions
Description: MabThera, administered by 2 infusions, 2 weeks apart
Study NCT02696876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthroscopic synovial brushing
Description: The specific and novel surgical procedure that will be carried out here is synovial membrane brushing using a novel device that has been shown to release MSCs from the synovium in vitro. This technique will be carried out in the setting of therapeutic microfracture for cartilage defects.
Study NCT02696876 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Microfracture or marrow-stimulation is a surgical procedure to repair small isolated cartilage defects by recruiting bone marrow mesenchymal stromal cells by creating small holes ('micro fractures') in the sub-chondral bone. These cells are entrapped in the ensuing blood clot and contribute to partial repair of the cartilage.
Study NCT00282672 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation System plus anti-secretory medication
Description: Treatment group subjects undergo up to 4 ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI).
Study NCT00282672 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure plus anti-secretory medication
Description: The Sham Control group undergo an upper endoscopy procedure with sizing of the esophageal diameter (a component of the ablation procedure steps, deemed the sham procedure) plus standard anti-secretory drug therapy (Proton pump inhibitor, PPI)
Study NCT02575716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videolaryngoscope
Description: Intubation with McGrath video laryngoscope after muscle relaxant
Study NCT02575716 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Videolaryngoscope
Description: Intubation with McGrath video laryngoscope after muscle relaxant
Study NCT01715662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wii.n.Walk
Description: Subjects will be trained using Nintendo Wii Fit (commercial fitness gaming software) for 40-minute sessions, 3x/week for 4 weeks. The intervention will initially be conducted in the clinic with a group of 3 participants and will graduate to in-home sessions starting from week 2.
Study NCT01715662 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Wii Big Brain
Description: Subjects in the control group will be trained using Wii Big Brain Academy Degree program which is a low-cost commercially available gaming software to improve cognitive function. The intervention will initially be conducted in the clinic with a group of 3 participants and will graduate to in-home sessions starting from week 2.
Study NCT01325311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Given PO
Study NCT01325311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genistein
Description: Given PO
Study NCT01325311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01325311 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01325311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01325311 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01325311 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT01696552 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TKR with Positioning Guides (PSPG)
Description: TKR (Vanguard Total Knee System, Biomet) with PSPG (Signature, Materialise) technique
Study NCT00944918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Intramuscular injection on days 1, 15, and 29 and then once monthly until disease progression.
Study NCT00944918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Tablet, oral, once daily until disease progression.
Study NCT00944918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: Tablet, oral, once daily until disease progression.
Study NCT03988361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Activated Cell Sorting
Description: At the moment of ICSI, sibling mature oocytes will be inseminated with spermatozoa from Study group or from Control group. Following ICSI, all the inseminated oocytes will be individually cultured in the same conditions in the same culture dish. The choice of embryo(s) for transfer will be based on embryo quality. The supernumerary good-quality embryos from both arms will be frozen for further use.
Study NCT00764101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification
Description: computerized training to reduce attentional bias in posttraumatic stress disorder
Study NCT00764101 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attentional Bias Modification
Description: computerized training to reduce attentional bias in posttraumatic stress disorder
Study NCT03361462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joyful Adventure Day
Description: Participants will participate in two joyful adventure days with adventure games and a short talk on SME (Sharing, Mind, Enjoyment) focusing on positive thinking and understanding of adolescent mental health problem (in particular the anxiety disorders) and mental well-being; provide physical activity diary, such as Zero-time Exercise after 1st session of adventure day, and invite family members / peers to join the competition at the 2nd session.
Study NCT03885414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-session Virtual Reality exposure therapy
Description: A series of exposure exercises (speech exercises) in front of a virtual audience, focusing on promoting inhibitory learning, with audio-feedback.
Study NCT03885414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-administered transition program
Description: Four-module internet program with weekly therapist guidance, focusing on transitioning to in-vivo exposure in everyday settings.
Study NCT01696552 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TKR with Conventional Technique
Description: TKR (Vanguard Total Knee System, Biomet) with Conventional Technique
Study NCT05702697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: focus extracorporeal shock wave therapy
Description: F-EWST with 0.15 mJ/mm2 intensity and 6 Hz frequency for 3 weeks. The shocking head was placed at the muscle positions of the long head of the bicep femoris, semitendinosus, and semimembranosus for 1,000, 500, and 500 shocks, respectively, accounting for 2,000 shocks in total/ session/week.
Study NCT05702697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home stretching program
Description: The leaflet on hamstring stretching exercises (in a sitting posture)
Study NCT05702697 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Home stretching program
Description: The leaflet on hamstring stretching exercises (in a sitting posture)
Study NCT04310930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amikacin
Description: Adults: Intravenous amikacin 5mg/kg once daily or 7.5mg/kg twice daily or 20-25 mg/kg thrice weekly. Children:Intravenous amikacin 15-30 mg/kg once daily, maximum dose 1500mg
Study NCT04310930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin
Description: Adults: Intravenous amikacin 5mg/kg once daily or 7.5mg/kg twice daily or 20-25 mg/kg thrice weekly. Children:Intravenous amikacin 15-30 mg/kg once daily, maximum dose 1500mg
Study NCT04310930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tigecycline
Description: Adults: Intravenous Tigecycline 25 mg increasing by 5 mg every two doses until either maximum dose reached (50mg) or until patient is unable to tolerate twice daily. Children (≥8 years of age) intravenous tigecycline: Day 1- 0.6mg/kg twice daily to a maximum of 25mg. Day 2- 0.6mg/kg (maximum 25mg) in the morning, 1.2 mg/kg (maximum 50mg) at night. Day 3- 1.2mg/kg (maximum 50 mg) twice daily
Study NCT04310930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: Adults: Intravenous Tigecycline 25 mg increasing by 5 mg every two doses until either maximum dose reached (50mg) or until patient is unable to tolerate twice daily. Children (≥8 years of age) intravenous tigecycline: Day 1- 0.6mg/kg twice daily to a maximum of 25mg. Day 2- 0.6mg/kg (maximum 25mg) in the morning, 1.2 mg/kg (maximum 50mg) at night. Day 3- 1.2mg/kg (maximum 50 mg) twice daily
Study NCT02861508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound
Study NCT02861508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Study NCT01095835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg
Description: PEG-IFN alfa-2a 180 micrograms (mcg) was administered subcutaneously, once weekly from Week 0 to 48.
Study NCT01095835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg
Description: PEG-IFN alfa-2a 135 mcg was administered subcutaneously, once weekly from Week 49 to 96.
Study NCT01095835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine (LAM)
Description: Lamivudine 100 milligrams (mg) was administered orally, daily from Week 0 to 48.
Study NCT01786057 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave therapy 1
Description: Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region and (400 shock waves/session of 0.2 mJ/mm2 per each trigger point) for gastrosoleus trigger points , 3 sessions at weekly intervals
Study NCT01786057 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Extracorporeal shock wave therapy 2
Description: Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region , 3 sessions at weekly intervals
Study NCT00350883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Description: Goal-oriented talk therapy
Study NCT00350883 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Keep getting usual care
Study NCT04437758 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen and Vitamin C powder mix nutritional intervention
Description: 20 g collagen + 50 mg vitamin C daily, 60 min prior to exercise
Study NCT04437758 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin placebo powder
Description: 20 g maltodextrin placebo daily, 60 min prior to exercise